article thumbnail

Daxxify, a New Anti-Wrinkle Drug and Botox Competitor is FDA-Approved

XTalks

Daxxify was FDA-approved for similar cosmetic purposes as Botox and other neuromodulators like Dysport and Xeomin. One of the first options made available for such purposes was Botox from Allergan, brought to health practitioners’ offices in 1989. A Novel Botox Competitor. Bringing Daxxify into Offices.

Botox 98
article thumbnail

FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label to Include Eight New Muscles to Treat Adults with Upper Limb Spasticity

The Pharma Data

are living with spasticity across a variety of neurologic conditions — BOTOX® has demonstrated efficacy and has an established safety profile with over 10 years of clinical use in adult upper limb spasticity. Senior Vice President, Chief Scientific Officer, BOTOX ® & Neurotoxins, AbbVie. million adults in the U.S.

Botox 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Allergan Aesthetics and BOTOX® Cosmetic (onabotulinumtoxinA) Put Real Stories at the Forefront in New Campaign

The Pharma Data

June 8, 2021 /PRNewswire/ — Allergan Aesthetics, an AbbVie company (NYSE: ABBV ), is changing the way BOTOX ® Cosmetic, the #1 selling neurotoxin treatment 1 , is connecting with consumers. “BOTOX ® Cosmetic is honoring and celebrating the dynamic people who use our products. IRVINE, Calif.

Botox 52
article thumbnail

AbbVie to Highlight Its Leadership in Movement Disorders at the.

The Pharma Data

” Researchers will present results from several studies in advanced Parkinson’s disease, including long-term, real-world data for DUODOPA ® (levodopa-carbidopa intestinal gel), as well as additional data on the long-term, real-world use of BOTOX ® (onabotulinumtoxinA) in patients with spasticity and cervical dystonia.

Botox 52
article thumbnail

U.S. FDA Accepts AbbVie’s New Drug Application for Atogepant for the Preventive Treatment of Migraine

The Pharma Data

2] – The atogepant application demonstrates AbbVie’s longstanding commitment to providing multiple migraine treatment options, including BOTOX® (onabotulinumtoxinA), a preventive treatment for those with chronic migraine, and UBRELVY® (ubrogepant), an acute treatment for adults with migraine. IMPORTANT SAFETY INFORMATION.

Botox 52
article thumbnail

Neuroscience Portfolio at the 2021 American Academy of Neurology (AAN) Annual Meeting

The Pharma Data

A total of 33 abstracts, including one podium presentation during the Clinical Trials Plenary Session and three oral presentations, will be shared from a broad range of studies across the spectrum of migraine, advanced Parkinson’s disease and spasticity. Clinical Trials Plenary Session. About BOTOX ®.

Botox 52
article thumbnail

Latest ABPI code breaches reveal the risk of ‘likes’ on LinkedIn

pharmaphorum

Allergan fell foul of the regulations for a number of LinkedIn and Instagram posts promoting Botox (botulinum toxin type A) to the public by the chief executive of aesthetics clinic – described in his profile as an ‘Allergan mentee’, which were also liked or commented on by employees of the company.

Botox 64